| Firm | Analyst |
|---|---|
| Bank of America | Geoff Meacham |
| Berenberg Capital Markets | Anita Dushyanth |
| Canaccord Genuity | Sumant Kulkarni |
| Goldman Sachs | Graig Suvannavejh |
| Guggenheim | Yatin Suneja |
| H.C. Wainwright | Ram Selvaraju |
| Jefferies | Chris Howerton |
| Rx Securities | Samir Devani |
| Truist Securities | Robyn Karnauskas |
| UBS | Colin Bristow |
BioXcel Therapeutics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding BioXcel Therapeutics, Inc.’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of BioXcel Therapeutics, Inc. or its management. BioXcel Therapeutics, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.